Sweden
· Delayed Price · Currency is SEK ODI Pharma AB Statistics
Total Valuation
ODI Pharma AB has a market cap or net worth of SEK 50.23 million. The enterprise value is 47.59 million.
| Market Cap | 50.23M |
| Enterprise Value | 47.59M |
Important Dates
The next estimated earnings date is Friday, November 22, 2024.
| Earnings Date | Nov 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ODI Pharma AB has 15.22 million shares outstanding. The number of shares has decreased by -0.76% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 15.22M |
| Shares Change (YoY) | -0.76% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 92.02% |
| Owned by Institutions (%) | n/a |
| Float | 1.21M |
Valuation Ratios
The trailing PE ratio is 141.10.
| PE Ratio | 141.10 |
| Forward PE | n/a |
| PS Ratio | 2.24 |
| PB Ratio | 22.65 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 133.69 |
| EV / Sales | 2.12 |
| EV / EBITDA | 38.93 |
| EV / EBIT | 39.03 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.22
| Current Ratio | 1.22 |
| Quick Ratio | 1.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 1.49 |
Financial Efficiency
Return on equity (ROE) is 14.86% and return on invested capital (ROIC) is 31.82%.
| Return on Equity (ROE) | 14.86% |
| Return on Assets (ROA) | 7.45% |
| Return on Capital (ROIC) | 31.82% |
| Revenue Per Employee | 22.45M |
| Profits Per Employee | 355,971 |
| Employee Count | 1 |
| Asset Turnover | 2.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.20% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.20% |
| 50-Day Moving Average | 3.82 |
| 200-Day Moving Average | 5.48 |
| Relative Strength Index (RSI) | 47.63 |
| Average Volume (20 Days) | 1,733 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ODI Pharma AB had revenue of SEK 22.45 million and earned 355,971 in profits. Earnings per share was 0.02.
| Revenue | 22.45M |
| Gross Profit | 4.78M |
| Operating Income | 1.22M |
| Pretax Income | 544,560 |
| Net Income | 355,971 |
| EBITDA | 1.22M |
| EBIT | 1.22M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
| Cash & Cash Equivalents | 2.64M |
| Total Debt | n/a |
| Net Cash | 2.64M |
| Net Cash Per Share | 0.17 |
| Equity (Book Value) | 2.22M |
| Book Value Per Share | 0.15 |
| Working Capital | 2.21M |
Cash Flow
| Operating Cash Flow | -3.64M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 21.31%, with operating and profit margins of 5.43% and 1.59%.
| Gross Margin | 21.31% |
| Operating Margin | 5.43% |
| Pretax Margin | 2.43% |
| Profit Margin | 1.59% |
| EBITDA Margin | 5.45% |
| EBIT Margin | 5.43% |
| FCF Margin | n/a |
Dividends & Yields
ODI Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.76% |
| Shareholder Yield | 0.76% |
| Earnings Yield | 0.71% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |